AstraZeneca Gets EU Approval for Ultomiris Drug
2022年9月23日 - 3:42PM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Friday that its Ultomiris drug has been
approved in the European Union for the treatment of adults with the
rare disease generalized myasthenia gravis.
The Anglo-Swedish pharma giant said that Ultomiris may reduce
treatment burden with dosing every eight weeks, it said, adding
that the drug also proved an improvement in activities of daily
living.
Generalized myasthenia gravis is a rare autoimmune neuromuscular
disease that leads to a loss of muscle function and severe
weakness, AstraZeneca said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 23, 2022 02:27 ET (06:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 3 2024 まで 4 2024
Astrazeneca (LSE:AZN)
過去 株価チャート
から 4 2023 まで 4 2024